These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34367166)

  • 41. Effects of exercise and anti-PD-1 on the tumour microenvironment.
    Buss LA; Williams T; Hock B; Ang AD; Robinson BA; Currie MJ; Dachs GU
    Immunol Lett; 2021 Nov; 239():60-71. PubMed ID: 34480981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
    Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
    Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor.
    Kagabu M; Yoshino N; Murakami K; Kawamura H; Sasaki Y; Muraki Y; Baba T
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
    Tian C; Liu J; Zhou H; Li J; Sun C; Zhu W; Yin Y; Li X
    Cancer Lett; 2021 Oct; 518():49-58. PubMed ID: 34139284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.
    Bartee MY; Dunlap KM; Bartee E
    Cancer Res; 2017 Jun; 77(11):2952-2963. PubMed ID: 28314785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
    Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
    Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
    Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
    Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
    Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
    Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
    Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers.
    Silva-Pilipich N; Smerdou C
    Clin Cancer Res; 2024 Sep; 30(17):3649-3651. PubMed ID: 38935348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
    Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.